X7 Clinicals and Pharmaceuticals Research EU OÜ
Private limited company
- 14119880
- EE102168471
- Harju maakond, Tallinn, Kesklinna linnaosa, Ahtri tn 8, 10151
Company X7 Clinicals and Pharmaceuticals Research EU OÜ has been registered on 26/09/2016. The status of the company is Active.
The net sales for 2024 were 102 287 euros. The net sales of X7 Clinicals and Pharmaceuticals Research EU OÜ decreased compared to 2023. The profit margin for 2024 is 10%. It has increased compared to 2023
The company's activity is Research and experimental development on natural sciences and engineering.
Empower Your Business
See all our solutions to grow your business
General Information
Company name in the business register
OÜ X7 Clinicals and Pharmaceuticals Research EU
Previous and other name(s)
X7 CLINICALS AND PHARMACEUTICALS RESEARCH EU OÜ
Company type
Private limited company
Registration number
14119880
D-U-N-S number
521905826
Registered
Sep 26, 2016 over 9 years ago
Registered capital
2,500 EUR
VAT number
EE102168471 from Jun 26, 2019 over 6 years
Status
Active
Contact data
Physical address
Harju maakond, Tallinn, Kesklinna linnaosa, Ahtri tn 8, 10151
E-mail address
Quarterly taxes paid
Source: Estonian Tax and Customs Board
Responsible persons
| Name | Personal ID / Date of birth | Role | From |
|---|---|---|---|
| Tatjana Semõkina | 47508×××××× | Management board member | Oct 12, 2020 |
| Olga Lembinen | 47603×××××× | Management board member | May 6, 2021 |
Source: Estonian Business Registry (RIK)
Representation rights
- Every member of the Management Board may represent the private limited company in concluding all transactions.
Source: Estonian Business Registry (RIK)
Shareholders, supervisory board and other persons
D&B Risk Analytics Compliance Intelligence
D&B Risk Analytics Compliance Intelligence provides compliance teams with industry-leading data and modern capabilities to manage third-party compliance risk. Through intelligent and highly configurable policy-based workflows, D&B Risk Analytics Compliance Intelligence provides a state-of-the-art automated KYC/KYB monitoring solution that helps companies stay informed of risks in near real-time.
Product is designed to help compliance teams quickly and efficiently review, assess, monitor, and manage entities and related parties, including beneficial owners and significant control persons.
More information
can be found in
Financial information
| 2024 | 2023 | 2022 | 2021 | ||||
|---|---|---|---|---|---|---|---|
| Revenue | 102 287 | ↓-37.33% | 163 220 | ↑18.84% | 137 344 | ↑27.39% | 107 812 |
| Net profit (loss) | 9 946 | ↑177.87% | -12 772 | ↑44.71% | -23 099 | ↓-150.70% | 45 563 |
| No of employees | 0 | ⹀ | 0 | ⹀ | 0 | ⹀ | 0 |
What are the company's liabilities, current assets, equity and balance volume?
Dun & Bradstreet Finance Analytics gives you access to additional economic indicators - short-term liabilities, current assets, equity and balance volume. Everything you need for credit risk management across companies of all sizes worldwide.
More information
can be found in